Myasthenia gravis classification
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Charmaine Patel, M.D. [2]
|
Myasthenia gravis Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Myasthenia gravis classification On the Web |
|
American Roentgen Ray Society Images of Myasthenia gravis classification |
|
Risk calculators and risk factors for Myasthenia gravis classification |
Overview
Classification
Myasthenia gravis may be classified into 3 subtypes based on presence of autoantibodies.
Pure ocular form
Ocular symptoms are the initial symptom in most of the MG cases. In about 15 percent of these patients this initial symptom will not progress to generalized disease after 2 years and they will classify as pure ocular form of the Myasthenia gravis. In approximately 50 percent of these patients we can’t detect antibodies by classical assay and we need to detect them through cell-based assay.[1]
Generalized form with anti-AChR antibodies
About 85 percent of MG patients develop generalized disease with autoantibody against AchR.[2] These antibodies are IgG1 and IgG3 subclasses which can bind to complement.[3] Thymic abnormalities are more common in this group, especially thymic follicular hyperplasia.[4] this subtype can be further divided into 2 groups:
- Early onset myasthenia gravis (onset of the disease before the age of 50 (EOMG)): In this group we have female predominance with the ratio of 3/1. Thymic follicular hyperplasia is more common in this group and is believed to be related to deregulation of sex hormones and their receptors on thymic cells.[5][6] These patients can have other autoimmune diseases like Hashimoto’s disease.[7]
- Late onset myasthenia gravis (onset of the disease after the age of 50 (LOMG)):
The forms without classical anti-AChR antibodies
- The form with anti-anti-MuSK antibodies
- The form with anti-LRP4 antibodies
- The form with clustered AChR antibodies
References
- ↑ Leite MI, Jacob S, Viegas S, Cossins J, Clover L, Morgan BP, Beeson D, Willcox N, Vincent A (July 2008). "IgG1 antibodies to acetylcholine receptors in 'seronegative' myasthenia gravis". Brain. 131 (Pt 7): 1940–52. doi:10.1093/brain/awn092. PMC 2442426. PMID 18515870.
- ↑ Vincent A, Newsom-Davis J (December 1985). "Acetylcholine receptor antibody as a diagnostic test for myasthenia gravis: results in 153 validated cases and 2967 diagnostic assays". J. Neurol. Neurosurg. Psychiatry. 48 (12): 1246–52. PMC 1028609. PMID 4087000.
- ↑ Verschuuren JJ, Huijbers MG, Plomp JJ, Niks EH, Molenaar PC, Martinez-Martinez P, Gomez AM, De Baets MH, Losen M (July 2013). "Pathophysiology of myasthenia gravis with antibodies to the acetylcholine receptor, muscle-specific kinase and low-density lipoprotein receptor-related protein 4". Autoimmun Rev. 12 (9): 918–23. doi:10.1016/j.autrev.2013.03.001. PMID 23535160.
- ↑ Berrih S, Morel E, Gaud C, Raimond F, Le Brigand H, Bach JF (January 1984). "Anti-AChR antibodies, thymic histology, and T cell subsets in myasthenia gravis". Neurology. 34 (1): 66–71. PMID 6228745.
- ↑ Eymard B, Berrih-Aknin S (January 1995). "[Role of the thymus in the physiopathology of myasthenia]". Rev. Neurol. (Paris) (in French). 151 (1): 6–15. PMID 7676132.
- ↑ Nancy P, Berrih-Aknin S (May 2005). "Differential estrogen receptor expression in autoimmune myasthenia gravis". Endocrinology. 146 (5): 2345–53. doi:10.1210/en.2004-1003. PMC 1839841. PMID 15661863.
- ↑ Klein R, Marx A, Ströbel P, Schalke B, Nix W, Willcox N (September 2013). "Autoimmune associations and autoantibody screening show focused recognition in patient subgroups with generalized myasthenia gravis". Hum. Immunol. 74 (9): 1184–93. doi:10.1016/j.humimm.2013.06.020. PMID 23792059.